|
SRRM2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.41030000402986E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.72739999993699E-07 |
| Normal-vs-Stage2 |
2.219900E-04 |
| Normal-vs-Stage3 |
2.50589999861717E-08 |
| Normal-vs-Stage4 |
8.12580000000285E-05 |
| Stage1-vs-Stage2 |
7.824200E-01 |
| Stage1-vs-Stage3 |
8.779700E-02 |
| Stage1-vs-Stage4 |
7.577400E-01 |
| Stage2-vs-Stage3 |
3.621800E-01 |
| Stage2-vs-Stage4 |
9.867200E-01 |
| Stage3-vs-Stage4 |
3.456800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.22110000000397E-07 |
| Normal-vs-AfricanAmerican |
3.953600E-02 |
| Normal-vs-Asian |
1.504620E-03 |
| Caucasian-vs-AfricanAmerican |
2.160200E-01 |
| Caucasian-vs-Asian |
4.097400E-01 |
| AfricanAmerican-vs-Asian |
5.847000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.69310000025713E-07 |
| Normal-vs-Female |
9.96919999884938E-08 |
| Male-vs-Female |
6.624200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.69469999999894E-06 |
| Normal-vs-Age(41-60Yrs) |
9.24780000022274E-07 |
| Normal-vs-Age(61-80Yrs) |
7.30679999949579E-07 |
| Normal-vs-Age(81-100Yrs) |
8.063400E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.017600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.518200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.156800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.518200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.016600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.547600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.368900E-04 |
| Classical-VS-Follicular |
4.146000E-02 |
| Classical-VS-Other |
1.840210E-01 |
| Classical-VS-Normal |
2.34489999995091E-06 |
| Tall-VS-Follicular |
2.599200E-01 |
| Tall-VS-Other |
9.180200E-01 |
| Tall-VS-Normal |
3.8368999977223E-08 |
| Follicular-VS-Other |
6.915400E-01 |
| Follicular-VS-Normal |
2.43680000000523E-06 |
| Other-VS-Normal |
7.317100E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.64700000029983E-07 |
| Normal-vs-N1 |
1.153150E-04 |
| N0-vs-N1 |
8.613200E-01 |
|
|
